Your browser doesn't support javascript.
loading
Evaluation of Tadalafil effect on lower urinary tract symptoms of benign prostatic hyperplasia in patients treated with standard medication
Madani, Ali Hamidi; Afsharimoghaddam, Amin; Roushani, Ali; Farzan, Alireza; Asadollahzade, Ahmad; Shakiba, Maryam.
  • Madani, Ali Hamidi; Guilan University of Medical Sciences. Urology Research Center.
  • Afsharimoghaddam, Amin; Guilan University of Medical Sciences. Urology Research Center.
  • Roushani, Ali; Guilan University of Medical Sciences. Urology Research Center.
  • Farzan, Alireza; Guilan University of Medical Sciences. Urology Research Center.
  • Asadollahzade, Ahmad; Guilan University of Medical Sciences. Urology Research Center.
  • Shakiba, Maryam; Guilan University of Medical Sciences. Urology Research Center.
Int. braz. j. urol ; 38(1): 33-39, Jan.-Feb. 2012. tab
Article in English | LILACS | ID: lil-623312
ABSTRACT

OBJECTIVES:

To evaluate safety and efficacy of tadalafil on lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in patients treated with standard medication. MATERIALS AND

METHODS:

In this case-controlled randomized clinical trial, from November 2008 to August 2009, 132 patients with obstructive and irritative urinary tract symptoms due to BPH, IPSS > 8, no indication for surgical intervention and that reached plateau levels of response to treatment were selected. These patients were randomly allocated in two groups (each containing 66 patients). The treatment group received standard treatment of BPH and tadalafil (10 mg nightly); the placebo group received only standard treatment of BPH. IPSS, maximum urinary flow rate (Qmax) and quality of life were assessed before and after a 3-month period of study.

RESULTS:

Before treatment, mean IPSS, Qmax and quality of life values in the treatment and placebo groups were 13.06 ± 4.37 and 13.66 ± 4.25, 8.92 ± 2.96 mL/s and 9.09 ± 2.91 mL/s, 2.93 ± 0.86 and 2.66 ± 0.78, respectively. After treatment, mean IPSS, Qmax, and quality of life values in treatment group were 7.66 ± 3.99, 9.99 ± 4.76 mL/s and 1.80 ± 0.98, respectively. These findings were compared to corresponding values of the placebo group (11.37 ± 3.64, 8.73 ± 2.22 mL/s and 2.19 ± 0.53, respectively) IPSS and quality of life were significantly different but Qmax didn't show a significant change.

CONCLUSIONS:

Tadalafil improves quality of life and urinary symptoms in patients with LUTS suggestive of BPH, but doesn't have any significant effect on Qmax. Therefore, this drug may be effectively used in combination with standard medical therapies for BPH.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Phosphodiesterase Inhibitors / Prostatic Hyperplasia / Carbolines / Lower Urinary Tract Symptoms / Erectile Dysfunction Type of study: Controlled clinical trial / Diagnostic study Limits: Aged / Humans / Male Language: English Journal: Int. braz. j. urol Journal subject: Urology Year: 2012 Type: Article Affiliation country: Iran

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Phosphodiesterase Inhibitors / Prostatic Hyperplasia / Carbolines / Lower Urinary Tract Symptoms / Erectile Dysfunction Type of study: Controlled clinical trial / Diagnostic study Limits: Aged / Humans / Male Language: English Journal: Int. braz. j. urol Journal subject: Urology Year: 2012 Type: Article Affiliation country: Iran